Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did the motion submitted by Inventiv lawyers intend to exclude discovery of the reasons why a potential monetary judgment will have been rendered against their client?
Enrollment completion likely entailed a milestone payment to CRO, just as it entailed milestone stock awards. It is possible that the cost uncertainties presented by ARB, FDA, & SEC were the primary reason Cel-Sci tepidly attempted to alter Investigation protocols by using knowable death rate timelines as a pretext to delay contractually bound payment to CRO.
Looks like navigators v pharmanet will see the 2018 judicial calendar while investors are left counting crows.
InVentiv, as a corporate entity after the merger, exists only for the sake of its ongoing litigation. Is the InVentiv v Navigator's case really a contest to decide how & when arbitration costs are written off (looks better for INC research if cost does not appear until 2018, I suspect) (while Navigators, as an established entity since 1974 & with a market cap of 1.6 billion & quarterly revenues of 300 million, would likely prefer to have the loss mitigate fy2017 taxes )....other questions to ask are 1) what is the coverage cap of PharmaNet's insurance policy & 2) what is the probability that an arbitration award to Cel-Sci will exceed coverage limits *thus entailing PharmaNet/ Inventiv/INC research must make up in payment***
...
I expect Cel-Sci to gain more than 50 million from arbitration with only a very slight chance that the award maxes at 100 million
Translation
InVentiv: "Our Navigator's Policy guarantees legal fee payment under the conditions we encounter no matter what"
Navigators: "It is unfair to make us pay legal bills if those legal bills mount in costs because InVentiv has been exploiting delays"
Has anyone calculated how much Cash cel-sci will generate if all available warrants are exercised? Determined expected share count? & weighted effective share price expectations....$125 warrant hypotheticals
Call JG Wentworth (855) 688-9669
All should sell because in December 2016 the FDA challenged CVM to demonstrate that its treatment protocol was not 'futile' . The fact that all subsequent FDA & cel-sci interactions focused only on the Investigator Brochure (after Cel-Sci recognized that incoming data did not require enrollment & survival rate changes to meet stated IND objectives) & not whether the Multikine protocol should be deemed 'futile' clearly is just obfuscation by a regulatory agency (the FDA) not beholden to transparency & its enforcement.
Standard of Care survival rates for Head & Neck Cancer max out around 10 months post treatment. Treatment becomes incrementally more toxic. It is, sadly, not outside the realm of possibility that the control group has already hit a high death number; thus leading to the withdrawal of IND enrollment amendment. If death rates in the MK group matched SOC, the FDA would have forced a study failure announcement rather than quibbling about Investigator Brochure details essential to potential fast track status (if this line of reasoning holds water)
Timmmmbbbbbeeeeeerrrrrrr............?
http://www.cbrneusa.com/sessions/state-of-the-art-projects-of-international-threat-reduction-initiatives/
Nuclear Smuggling Detection and Deterrence (NSDD)
JUPITR Biosurveillance Program in Korea
Integrated Multiplex Assay and Sampling System
Dr. Peter Emanuel, JPEO-CBD/ ECBC april 30, 2015 time 2:30-4:00pm
I thought the board would be ripe with speculative comments Today
Clearly you mean her performance is so derelict in merit that it helps to obscure the reputation dependent financial motives of Caragol & Silverman
OMG! How extraordinarily outrageous. Allison Tomek doesn't risk concern with callers looking to trade upon information that has not been formally made available to the public? If shareholders are to retain value in the company, its personnel must obviously be distracted by legal accusations at every turn. Really. It is as bad as a pharmaceutical company providing updates to patient enrollment in clinical trials without providing their personalized medical details/outcome.
1) A reverse split on a company up to date on its SEC filings will not occur until it has paid out all outstanding obligations to institutional investors.
2) Having said that We know that the total share cost for the approximately 5 million in provided/expected loans from institutional investors is 277,777,777 if today's open price (.0181) is assumed as the payout standard
3) average price is closer to .028 and 4 million of the 5 million has been paid out**going back 15 months
4) guesstimated Outstanding Shares after financing paid will be close to 400 million.....
5) Leaving 1.59 billion shares to be linked to future loans from institutional investors
6) If more loans are necessary to maintain steady state current operations, then about 15 months of additional share price discounting can be used before a Reverse Split would need to be given serious consideration by the the Board of Directors
7) Institutional investors make themselves available as loan providers so longs as the borrowing company maintains up to date filings & good accounting standards (Upon which Short interest institutional traders depend to maintain the allure of common stock to day traders.....
Make loans for stock & profit on both interest & short selling....what a deal especially if in the end the Products have merit...boing
JUPITR Undergoes Tech Demo at Dugway, Heads to South Korea - See more at:
http://globalbiodefense.com/2015/04/22/jupitr-biosurveillance-dugway-south-korea/
An innovative system to warn of a biological attack recently underwent an advanced technical demonstration at Dugway Proving Ground, or DPG, and is now in South Korea for an operations demonstration by Soldiers.
The Joint U.S. Forces Korea Portal and Integrated Threat Recognition, or JUPITR, system employs a variety of detectors working together to enhance biosurveillance, and reduce false positives.
“It’s a system of systems approach toward biological detection,” said Russ Bartholomew of DPG’s Life Sciences Division, and test officer for the JUPITR advanced technical demonstration at DPG.
Detecting harmful microbes within a natural background of airborne materials is a daunting, complex task. Bartholomew said that JUPITR is an array of instruments that includes acoustic, seismic, motion and other sensors with chemical and biological detectors. In a suspected biological attack, data from each instrument is scrutinized determine whether an attack occurred, and what type.
The Department of Defense defines a system of systems approach as, “a set or arrangement of systems that results when independent and useful systems are integrated into a larger system that delivers unique capabilities.”
Recently, at one of DPG’s massive outdoor test grids, JUPITR’s sensors were set in an array identical to the South Korea configuration. Benign microbes with characteristics similar to biological agents were released in varying scenarios, simulating biological attacks. Each scenario was electronically recorded, for playback at the South Korea operations demonstration.
“When they hit play, all the Soldiers will react to what was actually done at Dugway,” Bartholomew said.
The JUPITR system will return to DPG this summer for new biological detector testing at the recently-completed Whole System Live Agent Test, or WSLAT, chamber. Testing will determine which bio-detector is best for JUPITR.
“What we will test and evaluate is the degree of sensitivity and specificity of these sensors to BSL-3 agents,” said Aaron Thomas, a DPG microbiologist.
This marks the first test for the newly built WSLAT, believed to be the world’s largest chamber of its kind. Since their inception, biological detectors throughout the world have had their detection components removed for live-agent testing in small chambers. WSLAT’s walk-in chamber allows the testing of more than one detector, in its entirety.
JUPITR’s new detectors will be exposed to live, Biosafety Level 3 agents – those for which there is a cure or vaccine. To simulate authentic use, environmental factors such as temperature extremes, humidity and wind may also be introduced in the chamber.
The JUPITR program is overseen by the Army’s System of Systems Engineering and Integration Directorate, and the U.S. Army Edgewood Chemical Biological Center in Maryland.
The program was created in response to a presidential directive and national strategies that recognize a biological attack’s effect on national security, and the need to protect the Asia-Pacific region. Support organizations for JUPITR include the Department of Homeland Security, Office of the Secretary of Defense and the Defense Threat Reduction Agency.
the Year Old backlogged revenue and MBAND earnings have already been factored into share price (& Not Set Toward Shareholder Dividends). Share price is drifting down because the value potential of its MBAND component depends ever more upon prospective information. From Aberdeen to Korea to???>>Utah......
Technology grants are not revenue. They are governed by strict accounting oversignt under a Payment Management System & awards are subject to numerous performance & timetable adherence suspension provisions.
Notice of Awards do provide Market Makers with asset valuations for derivative instrument metrics.............
I'd like to think that firefly DX press releases were coincidently made as the company submitted new Just In Time details for grant review and that W. Caragol is now acting as a signing official for a grant award negotiation during his visit to Washington..........Nonetheless, I am distressed by the lack of news from the MBAND review by the JUPITR program (with june biodetection testing at the Utah facility I really believed that a technology award for specs would have had to have been made to accord a 60 day achievement window......)
If MBand (&? firefly) are to be tested, I expect some kind of technology award from the Department of the Army, DOD, DHS, &/or Dept of Interior to pay for specifications. JUPITR search results also revealed that Peter Emanuel will be speaking about detection technologies on 4/30/2015
I believe other board members discovered 4 related Federal biz opportunity awards scheduled for determination during this time period for which PSID could win a contract .
I don't know what to make of the attentive early filing of the 10k (breaks a pattern) nor do I know whether or not changes to authorized shares are a positive or negative sign and whether those AS changes are related to the timely 10k
From test tube to battlefield
http://soldiers.dodlive.mil/2015/03/from-test-tube-to-battlefield/
Dugway Proving Ground, almost two hours outside Salt Lake City, is nestled among three mountain ranges in Utah. It’s remote desert location and ample size — roughly 1,300 square miles — make it the ideal place for testing artillery, and chemical and biological agents.
“Dugway Proving Ground is a test and evaluation proving ground,” Col. Ron Fizer, base commander, said. “Because of that we run a range of tests, primarily associated with our mission to provide chemical and biological offense equipment to our warfighters, as well as help support the national defense strategy for counteracting WMD, or weapons of mass destruction, with capabilities that have been validated here before we put them in the hands of the warfighter.”
The proving ground operates on a “test tube to battlefield” concept, meaning that any equipment tested here has been certified, from small-scale lab experiments through real-time range and environmental testing.
West Desert Test Center
All the testing activities on DPG happen at the West Desert Test Center, several miles from Dugway’s headquarters.
“We have eight divisions that help execute all that testing, from the labs and the chamber testing … out to the test grids with our air field and range control,” Ryan Harris, director of the test center, explained.
Additionally, the center often hosts Utah National Guard units for their two-week training periods, and sometimes hosts Guard units from other states. “There are a lot of field artillery units out in Utah, and they’ll come out and do a lot of their live-fire exercises,” Harris said.
In addition to artillery testing, the center is also responsible for chemical and biological testing in the laboratory and on the range.
The Chemical Test Division is upgrading its test grid network to enable field-testing with real-time data collection over a wireless network.
“When you have to collect all that data manually, it’s usually days or weeks before you can go through that and make an adjustment to a test trial,” Harris said. “With this new system, we’ll be able to make that within hours or … a day and … get more valuable data … for a reduced cost and schedule.”
The division tests chemical warfare agents, nerve agents and industrial toxins, starting on a small scale first. For example, Harris said they test protective clothing against agents. “We’ll test swatches … of material. The material performs at the standards it needs to before they go to a full systems test, where they test the whole ensemble,” he explained. The division also has the capability of chamber testing objects as large as an M1 Abrams tank to evaluate them for decontamination solutions.
“We’re fully capable of testing the Department of Defense defense systems, both on the chemical and biological side of the house, with all those test capabilities we have,” Harris said.
The Life Sciences Division, where biological testing occurs, is in the final certification phase for the Whole System Live Agent Test chamber, which will enable entire pieces of detection equipment to be tested against biological aerosol agents.
“The chamber itself is a brand new capability for the Department of Defense. It’s really a brand new capability for our nation, because it’s an asset for everyone,” Douglas Andersen, chief of the Life Sciences Division, said. The division’s primary mission is detector testing, but they also conduct decontamination testing and training, he added.
The WSLAT is an ideal addition to the test center because it is large enough to contain not only whole pieces of detection equipment, but also multiple systems at once, allowing them to be compared to one another and evaluated against aerosol agents, Andersen said.
JUPITR program and the S/K Challenge
The JUPITR program, or Joint USFK Portal and Integrated Threat Recognition, is designed to enhance ability of warfighters stationed in Korea to detect and then respond to a biological attack without there being a mission impact, should such an attack occur during an Army operation, Fizer explained. The program, which is an “advanced technology demonstration,” is used to evaluate the integration of force protection, chemical and biological sensors.
“JUPITR is an exciting program because it’s going to allow an integrated defense for bases, potentially across the world,” Andersen said. “It is an array of sensors that eventually would be deployed and work in a unified way … to identify threats and help commanders in the field make decisions based on that threat.”
The S/K Challenge is an initiative within the chemical/biological defense program, Harris explained. It is an annual event, now in its second year, designated to give chemical and biological detection equipment in development a chance for early testing. Challenge participants include the Department of Defense, other federal agencies and industry partners, as well as international allies.
“To be able to have their systems … exposed to the environment to see how well they perform … it gives them the opportunity to make adjustments early in the materiel development process to ensure they can make tweaks … then, rather than when they go back for evaluation,” Harris said.
The Challenge benefits the Army in several ways, primarily through cost reduction, a result of joint testing. The Army may also be able to identify new technologies, where to improve existing technologies, or even establish partnerships with other participants to bring technology to the Soldier more quickly, Fizer said.
“So, overall, we’ll get the best capabilities that we can get for the warfighter, as far as chemical and biological detection goes,” added Capt. Michael Stewart, Joint Executive Program Office for Chemical and Biological Detection liaison officer.
This year, the Challenge will take place in the first half of June, where participants will conduct chamber testing on their equipment, Stewart said. The equipment will be placed inside either an ambient testing chamber or an active standoff chamber and exposed to chemical agents.
If testing is conducted outside, non-harmful simulants are used to mimic the same physical characteristics of the agent, Harris explained.
Dugway’s thorough testing protocols and exclusivity — there’s no other major chemical and biological agent testing facility in the Department of Defense — make it unique, Fizer said. The proving ground has been in operation since 1942 and is continually evolving with the threats facing the nation.
“Dugway Proving Ground continues to evolve and adapt to provide answers to not just our warfighters, but our emergency responders,” Fizer continued, “so that if it’s an anthrax release in a forward operating area, such as Iraq, Afghanistan, Korea, or it’s an anthrax release here in the U.S. (at) a sporting even such as the Super Bowl … we’re going to provide technology that has been validated all the way from the laboratory to the field.”
1) Until DHS FY2015 is approved none of the $30 million scheduled as grant awards to municipalities and transportation hubs will be processed.
2)Biodetection specific work orders for the new lab in Utah will not be filed or filled.
3) DHS funding of next generation handheld PCR assays also awaits FY2015 DHS budget approval .....20 minutes is a substantial improvement upon an hour ***thorough evaluation & testing are required to address the continuing point of use market time costs ***Widespread use requires results in less than a minute***** Do you know understand why ST makes meaningful grant awards to medical technology firms? (conferences, technical papers, redesigns, new patents, politics, competition, )
FY2016 http://www.dhs.gov/sites/default/files/publications/FY_2016_DHS_Budget_in_Brief.pdf
Only those with proper security clearance can see the Allocation Balance Sheets & Schedule for SenseNet.
Republicans can fund DHS for the purposes they desire so long as their riders "Prioritize" terrorist related responsibilities and training-field sampling & testing - (INS, DEA, ICE, etc) over contradictory immigration enforcement. A shutdown of DHS for any duration creates economic catastrophes, so.....55 is done.
Inevitable DHS 2/27 funding is immaterial to the inaccessible answer puzzling those interested in SenseNet Grant Awards Processing under the full funding of DHS by the Continuing Resolution.
The closing Bid/Ask prices can be read as "bid goodbye to Virgin America capital flight #22 San Francisco."
DHS continuing resolution expires Feb 27th. If we are working our thumbs in anticipation of a SenseNet grant for Firefly DX, then our obstacles may be depending upon the budgeting priorities of the CR.
Final Exams or will MBand be tested at sea?
http://www.cbrneportal.com/interview-with-dr-peter-emanuel-the-joint-united-states-forces-korea-portal-and-integrated-threat-recognition/
I see with the BICS and BSP you are already in a very advanced stage. How far are you with the third leg, the assessment of the environmental detectors (AED)?
Well, if you asked me that question at the beginning of the summer I would have had a different answer, but now we’re in full swing with AED. So the idea with AED is that we’re looking to replace our older legacy systems: they’re expensive, they have a high training burden. So we believe our goal is to increase the performance of the systems, lower the training burden and lower the total life cycle costs of the systems. However, we’re not looking to select “one ring to rule them all”. We may end up selecting different systems for different needs, but this is the largest side-by-side assessment we’ve ever done.
Ten systems have been selected, while some of them have been drawn from the DHS efforts. First we bought four of every system. Two systems went over to Osan Air Base and they were turned on at the beginning of September at an airfield and they were run up until about last week. We didn’t attack them or anything, but we wanted to see whether they broke, how they did in the rain, in the sun.
Meanwhile, two more systems were flown to the two hundred foot long Ambient Breeze Tunnel and they were assessed by challenging them with 152 aerosol challenges of four different agents: anthrax, plague, bacillia and botoxin, and that assessment finished Friday. Those systems departed afterwards for the Naval Research Laboratory (NRL) and they are set to arrive tomorrow morning, undergoing a maritime excursion in an environment that simulates a naval vessel. This test will run through February 4, if we keep on schedule.
From there, we can begin to make decisions on how we proceed into the final exams, which we call the Operational Demonstration. The Operational Demonstration is overseen by the Army Testing and Evaluation Center. They work with the Operational Test Command, and they perform what they call a joint military utility assessment – a fancy phrase for our final exams. And those systems that pass the final exam then move forward and potentially serve the purpose of achieving a residual capability that will remain with USFK. Obviously everything that fails to demonstrate military utility is removed from theatre, because we only want to put the best of the best out there.
So to conclude, AED is still in motion right now, I’m actually set to get a snapshot of how that data looked after the holidays and then I should get the maritime excursion data sometime around Valentine’s Day.
The Amended Certificate of Designation was filed to increase the authorized shares of Series I Convertible Preferred Stock from 1,000 shares to 2,500 shares. No other terms were modified or amended in the Amended Certificate of Designation.
From 10K
. As a result of the voting rights associated with the Company’s 1,000 shares of Series I Preferred Stock, the named executive officers and directors have the right to 720.6 million votes as the result of their Series I holdings. The percentage of voting rights in the table below assumes that all Series I shares held by directors and named officers are voted in any instance requiring shareholder vote.
(1) Mr. Caragol beneficially owns 24,507,654 shares, which includes 10,000 shares issuable upon the exercise of warrants and shares issuable upon the exercise of stock options that are currently exercisable or exercisable within 60 days of March 17, 2014. Mr. Caragol has sole voting power over 1,651,916 shares of our common stock. Mr. Caragol has sole dispositive power over 223,000 shares of our common stock. Mr. Caragol lacks dispositive power over 1,438,916 shares which are restricted as to transfer until January 1, 2015 (200,000 shares), and January 1, 2016 (1,226,916 shares). Mr. Caragol owns 631 shares of Series I preferred stock, which may convert to 22,845,738 shares of common stock. The Series I preferred stock vests on January 1, 2016.
(2)
Ironridge Global Partners, LLC, or IGP, and IGP's managing members Brendan T. O'Neil, Richard H. Kreger, John C. Kirkland and Keith Coulston may be deemed to beneficially own shares of common stock beneficially owned by Ironridge Global IV, Ltd., or “IV”, and shares of common stock beneficially owned by Ironridge Global III, LLC, or “III”, including shares issuable to III upon conversion of the Series F Preferred Stock. The address of the principal business office of IV is Harbour House, 2nd Floor, Waterfront Drive, P.O. Box 972, Road Town, Tortola, British Virgin Islands VGlliO. The address of the principal business office of IGP, III, and Messrs. O'Neil, Kreger and Coulston is 425 California Street, Suite 1010, San Francisco, California 94104. The address of the principal business office of Mr. Kirkland is 88I Alma Real Drive, Suite 305, Los Angeles, California 90272. Voting and dispositive power with respect to the shares owned by IV is exercised by David Sims and Peter Cooper, Directors. Voting and dispositive power with respect to shares of our common stock owned by III is exercised by Mr. O'Neil and Mr. Coulston. However, for so long as III or IV or any of their affiliates, or Ironridge, hold any shares of our common stock, they are prohibited from, among other actions: (1) voting any shares of our common stock owned or controlled by them, or soliciting any proxies or seeking to advise or influence any person with respect to any voting securities of the issuer; (2) engaging or participating in any actions or plans that relate to or would result in, among other things, (a) acquiring additional securities of us, alone or together with any other person, which would result in them collectively beneficially owning or controlling, or being deemed to beneficially own or control, more than 9.99% of our total outstanding common stock or other voting securities, (b) an extraordinary corporate transaction such as a merger, reorganization or liquidation, (c) a sale or transfer of a material amount of assets, (d) changes in our present board of directors or management, (e) material changes in our capitalization or dividend policy, (f) any other material change in our business or corporate structure, (g) actions which may impede the acquisition of control us by any person or entity, (h) causing a class of our securities to be delisted, (i) causing a class of our equity securities to become eligible for termination of registration; or (3) any actions similar to the foregoing. Each ofiGP and Messrs. O'Neil, Kreger, Kirkland and Coulston disclaims beneficial ownership or control of any of the securities listed above. IGP and Messrs. O'Neil, Kreger, Kirkland and Coulston directly own no shares of the issuer. However, by reason of the provisions of Rule 13d-3 of the Exchange Act, as amended, IGP or Messrs. O'Neil, Kreger, Kirkland and Coulston may be deemed to beneficially own or control the shares owned by III and IV. Messrs. O'Neil, Kreger and Kirkland are each managing directors of III and IV, and managing directors, members and 30% beneficial owners of IGP. Mr. Coulston is a director, member and 10% beneficial owner of IGP. IGP is a member and beneficial owner of III, and a stockholder and beneficial owner of IV.
For purposes of calculating the percent of class, we have assumed that there were a total of 70,500,092 shares of our common stock outstanding such that 7,042,959 shares beneficially owned would represent approximately 9.99% of the outstanding common stock after such issuance. The 9.99% ownership limitation does not prevent Ironridge from selling some of its holdings and then receiving additional shares. In this way, Ironridge could sell more than the 9.99% ownership limitation while never holding more than this limit. The Series F Preferred Stock has a provision precluding III from converting any shares of Series F Preferred Stock if such conversion would result in Ironridge being deemed to beneficially own or control more than 9.99% of our outstanding common stock. Subject to the foregoing overall limitation, shares include (I) 7,042,959 shares of common stock beneficially owned by Ironridge, (2) 13,276,523 shares of common stock issuable upon conversion of 700 shares of the Series F Preferred Stock, and (3) a number of shares of common stock issuable upon conversion of any additional shares of Series F Preferred Stock that we may choose to issue in lieu of cash as payment of the 7.65% dividends on the Series F Preferred Stock.
(3) Includes 574,800 shares of our common stock and 37,750 shares of our common stock issuable upon the exercise of stock options that are currently exercisable or exercisable within 60 days of March 17, 2014. Mr. Cobb lacks dispositive power over 60,000 shares, which are restricted until January 1, 2016. Mr. Cobb owns 63 shares of Series I preferred stock, which may convert to 2,097,199 shares of common stock. The Series I preferred stock vests on January 1, 2016.
(4) Includes 622,800 shares of our common stock and 36,000 shares of our common stock issuable upon the exercise of stock options that are currently exercisable or exercisable within 60 days of March 17, 2014. Mr. Krawitz lacks dispositive power over 100,000 shares, which are restricted until January 1, 2016. Mr. Krawitz owns 76 shares of Series I preferred stock, which may convert to 2,468,283 shares of common stock. The Series I preferred stock vests on January 1, 2016.
(5) Includes 631,076 shares of our common stock and 36,000 shares of our common stock issuable upon the exercise of stock options that are currently exercisable or exercisable within 60 days of March 17, 2014. Mr. Siegel lacks dispositive power over 120,000 shares, which are restricted until January 1, 2016. Mr. Siegel owns 39 shares of Series I preferred stock, which may convert to 1,412,122 shares of common stock. The Series I preferred stock vests on January 1, 2016.
Who are the 1500 additional preferred shares for? I haven't found any indication of ownership designation within prior 8Ks.
TAC BIO II uses Firefly Luciferase for bioluminescence. Does Shell3 want to inform the board as to whom the patent for TAC BIO II was licensed by ECBC?
A 4/25/14 Blog Post on medium.com that dismisses BSP budgeting is apparently considered as valuable due diligence as is ignoring preliminary scoring for large BSP units when attempting to ascertain which tested products are likely to advance to OT&E according to the "usual" PSID detractors on this messageboard.
The Pre-Upgrade evaluations have been online for a long time
http://www.wmddetectorselector.army.mil/#Biological&Chemical&Radiological&Large&page=1&scenario=Mob&sort=scenario
The Pre-Upgrade evaluations have been online for a long time
http://www.wmddetectorselector.army.mil/#Biological&Chemical&Radiological&Large&page=1&scenario=Mob&sort=scenario
Field Scores from Korea will be reported after the Holidays
http://www.wmddetectorselector.army.mil/PDFs/185.pdf MBAND
Operations:
• Can be used from < -21°C to > 42°C (All temperatures)
• Components must be stored at 4°C
• Performance is not influenced by relative humidity
• Between 1 to 3 years shelf life
• 5-10 years expected life
• Results cannot be viewed in real-time
• The system or device is currently fully autonomous
• The system software is open and available for modification
• The system hardware is open and available for modification
Detection:
• Greater than 250 µL
• Superior specificity. System has a false alarm rate approaching
zero (~0%)
• 100-1,000 CFU per mL
• 100-1,000 PFU per mL
• 1-10 ng per mL
• Fully automated spore lysis
http://www.wmddetectorselector.army.mil/PDFs/219.pdf IBIS
Operations:
• Can be used from 4°C to 37°C
• Components must be frozen (-20°C)
• Device or system has peak performance at normal relative
humidity conditions
• Between 6 months and 1 year shelf life
• 5-10 years expected life
• Results can be viewed in real-time
• The system is not capable of autonomy
• The system software is closed and not available for
modification
• The system hardware is closed and not available for
modification
Detection:
• Efforts are underway to achieve 510K clearance
• Efforts are underway to achieve FDA approval
• Less than 100 µL
• Excellent specificity. System has occasional false alarms under
certain conditions (<2%)
• 100-1,000 CFU per mL
• 100-1,000 PFU per mL
• Semi-automated spore lysis
http://www.wmddetectorselector.army.mil/PDFs/158.pdf
Joint Biological Standoff
Detection System, Increment 1
Operations:
• Can be used from -21°C to 41°C
• Device or system has peak performance at normal relative
humidity conditions
• Between 1 to 3 years shelf life
• Greater than 10 years expected life
• Results can be viewed in real-time
• The system or device is currently fully autonomous
• The system software is open and available for modification
• The system hardware is open and available for modification
Detection:
• This system does not test liquids
• Poor specificity. System has a consistently high level of false
alarms (>10%)
• Spore lysis not necessary for detection by system
EDITORIALS HEADLINE THREATS
The JUPITR ATD Program – Interview with Dr. Peter Emanuel
http://www.cbrneportal.com/interview-with-dr-peter-emanuel-the-joint-united-states-forces-korea-portal-and-integrated-threat-recognition/
Upgrading Biosurveillance Capabilities on the Korean Peninsula
Led by the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) and supported by the U.S. Army Edgewood Chemical Biological Center (ECBC), the Joint United States Forces Korea Portal and Integrated Threat Recognition (JUPITR ATD) will respond to needs and requirements in the field of biological defense. While establishing a Biosurveillance Portal (BSP) and assessing Biological Identification Capability Sets (BICS), Environmental Detectors (AED) and an Early Warning Concept, JUPITR ATD will provide unique biological detection capabilities in order to address the demand for stronger biosurveillance capabilities on the Korean Peninsula. Not only against the background of the Ebola Outbreak in West-Africa, the JUPITR ATD program is a highly sophisticated approach in times of need.
Now that the program is running for almost 2 years, IB Consultancy took the opportunity to talk to Dr. Peter Emanuel, ECBC BioSciences Division Chief & JPEO-CBD JUPITR ATD Lead, in order to get an update about the current status quo and respective findings of JUPITR ATD. The interview was held on December 4.
Positive ID should join the Cortelazzi Consortium....This Stinks!!!Goodbye
Wed-ish 10Q and Revenue Update news release driving price uptick, Appears to be good time to double down on investment
If GlucoChip remained as PSID asset, all related market infiltration accounting charges would hurt the company's balance (thus detracting from MBand & FireFly financing/grant/contract opportunities).
PSID management, by transferring product ownership in exchange for common stock and interest bearing warrants, have instead turned GlucoChip into a value certain balance sheet asset.
GlucoChip (PotassChip, Hematochip, PharmaceuticalChip, etc) moved off PSID books for a few years as emphasis given to marketing of MBand & Firefly from which it is a conceptual derivative....Welcome to the ground floor of a next generation Medical Device Manufacturer
It is not illegal to borrow money to pay salaries; issue press releases expressing rights to prospective business activities; and repay interest on salary debt by issuing shares....matryoshka doll (serfcorp)....Ranting about losses and legality is pointless. If you attend the right finishing schools, the fraternal system will support opportunities for an entrepreneurial legacy within the lawful boundaries of corporate finance.
Social differentiation is not equivalent to genetic or informed talents. (Subculture of shark week where the threatening weak are not human but chum)